Novo Nordisk (NVO) has released an update.
Novo Nordisk A/S has successfully completed its share repurchase program, acquiring B shares for DKK 2.1 billion from February to April 2024. The company, a leader in global healthcare, continues its commitment to defeating chronic diseases with an additional B share repurchase plan for DKK 20 billion over the next 12 months. Novo Nordisk, known for its diabetes care legacy, employs over 63,000 people and serves markets in 170 countries.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.